Geoff Meacham
Stock Analyst at Citigroup
(3.46)
# 956
Out of 4,732 analysts
222
Total ratings
49.64%
Success rate
3.67%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $895 → $795 | $681.58 | +16.64% | 19 | Jan 14, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $98 → $85 | $40.53 | +109.72% | 2 | Jan 7, 2025 | |
| BTAI BioXcel Therapeutics | Downgrades: Underperform | $7 → $0.25 | $0.34 | -27.33% | 5 | Jan 7, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Buy | $22 → $7 | $2.05 | +241.46% | 2 | Jan 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $42 → $45 | $33.79 | +33.18% | 5 | Nov 25, 2024 | |
| GILD Gilead Sciences | Initiates: Buy | $125 | $91.84 | +36.11% | 6 | Nov 14, 2024 | |
| BIIB Biogen | Initiates: Neutral | $190 | $140.55 | +35.18% | 12 | Nov 14, 2024 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $575 | $422.00 | +36.26% | 4 | Nov 14, 2024 | |
| AMGN Amgen | Initiates: Neutral | $335 | $272.11 | +23.11% | 10 | Nov 14, 2024 | |
| ABBV AbbVie | Maintains: Buy | $226 → $215 | $171.56 | +25.32% | 14 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $725.72 | +51.57% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $1 | $0.58 | +73.76% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $16.19 | +91.48% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $115 | $61.53 | +86.90% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $110 | $34.06 | +222.96% | 9 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $0.44 | +2,167.57% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $145 | $97.92 | +48.08% | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $45 | $28.92 | +55.60% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $37.06 | +115.87% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $147.03 | +15.62% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $38 | $30.75 | +23.58% | 2 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $48 | $40.72 | +17.88% | 2 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $30 | $40.61 | -26.13% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $56.29 | +6.59% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 | $1.77 | +351.98% | 2 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $10.11 | +38.48% | 2 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $4.10 | +95.12% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.31 | +1,197.71% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $14 | $1.65 | +748.48% | 3 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $45 | $26.30 | +71.10% | 6 | Apr 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $3.60 | +1,288.89% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $2.08 | +1,053.85% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $9.33 | -57.13% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $34 | $18.54 | +83.39% | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.85 | +1,413.51% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $0.91 | +3,639.14% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $6.16 | +809.09% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.21 | +1,483.71% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $5.13 | +10,135.91% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.37 | +2,965.69% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $6.26 | +219.49% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $1.09 | +1,734.86% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $2.97 | +203.03% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $7.37 | +714.11% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $7 | $3.47 | +101.73% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $13.88 | +65.71% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $71.93 | +14.00% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $358.93 | -73.53% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $4.47 | +1,691.71% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $40 | $43.84 | -8.76% | 7 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $143.26 | -5.77% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.77 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.66 | +446.45% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $37.59 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $246.27 | -35.84% | 5 | Nov 8, 2017 |
Regeneron Pharmaceuticals
Jan 14, 2025
Maintains: Neutral
Price Target: $895 → $795
Current: $681.58
Upside: +16.64%
CRISPR Therapeutics AG
Jan 7, 2025
Maintains: Buy
Price Target: $98 → $85
Current: $40.53
Upside: +109.72%
BioXcel Therapeutics
Jan 7, 2025
Downgrades: Underperform
Price Target: $7 → $0.25
Current: $0.34
Upside: -27.33%
Neumora Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $22 → $7
Current: $2.05
Upside: +241.46%
BridgeBio Pharma
Nov 25, 2024
Maintains: Buy
Price Target: $42 → $45
Current: $33.79
Upside: +33.18%
Gilead Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $125
Current: $91.84
Upside: +36.11%
Biogen
Nov 14, 2024
Initiates: Neutral
Price Target: $190
Current: $140.55
Upside: +35.18%
Vertex Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $575
Current: $422.00
Upside: +36.26%
Amgen
Nov 14, 2024
Initiates: Neutral
Price Target: $335
Current: $272.11
Upside: +23.11%
AbbVie
Nov 12, 2024
Maintains: Buy
Price Target: $226 → $215
Current: $171.56
Upside: +25.32%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $725.72
Upside: +51.57%
Oct 30, 2024
Downgrades: Underperform
Price Target: $6 → $1
Current: $0.58
Upside: +73.76%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $16.19
Upside: +91.48%
Sep 17, 2024
Maintains: Buy
Price Target: $130 → $115
Current: $61.53
Upside: +86.90%
Sep 13, 2024
Maintains: Neutral
Price Target: $130 → $110
Current: $34.06
Upside: +222.96%
Aug 19, 2024
Maintains: Buy
Price Target: $12 → $10
Current: $0.44
Upside: +2,167.57%
Jul 31, 2024
Maintains: Buy
Price Target: $150 → $145
Current: $97.92
Upside: +48.08%
Jun 13, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $28.92
Upside: +55.60%
May 10, 2024
Initiates: Buy
Price Target: $80
Current: $37.06
Upside: +115.87%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $147.03
Upside: +15.62%
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $30.75
Upside: +23.58%
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $40.72
Upside: +17.88%
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $40.61
Upside: -26.13%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $56.29
Upside: +6.59%
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $1.77
Upside: +351.98%
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $10.11
Upside: +38.48%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $4.10
Upside: +95.12%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.31
Upside: +1,197.71%
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $1.65
Upside: +748.48%
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $26.30
Upside: +71.10%
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $3.60
Upside: +1,288.89%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $2.08
Upside: +1,053.85%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $9.33
Upside: -57.13%
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $18.54
Upside: +83.39%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $1.85
Upside: +1,413.51%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $0.91
Upside: +3,639.14%
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $6.16
Upside: +809.09%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.21
Upside: +1,483.71%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $5.13
Upside: +10,135.91%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.37
Upside: +2,965.69%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $6.26
Upside: +219.49%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $1.09
Upside: +1,734.86%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $2.97
Upside: +203.03%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $7.37
Upside: +714.11%
Jun 25, 2020
Initiates: Underperform
Price Target: $7
Current: $3.47
Upside: +101.73%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $13.88
Upside: +65.71%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $71.93
Upside: +14.00%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $358.93
Upside: -73.53%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $4.47
Upside: +1,691.71%
Nov 6, 2018
Maintains: Equal-Weight
Price Target: $43 → $40
Current: $43.84
Upside: -8.76%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $143.26
Upside: -5.77%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $13.77
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.66
Upside: +446.45%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $37.59
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $246.27
Upside: -35.84%